Harry Walmsley
About Harry Walmsley
Harry Walmsley is a QC Analytical Scientist specializing in analytical science within the field of gene therapy. He has worked at MeiraGTx in London since 2019 and holds a Bachelor of Biomedical Science from Victoria University of Wellington.
Work at MeiraGTx
Harry Walmsley has been employed at MeiraGTx as a QC Analytical Scientist since 2019. In this role, he focuses on analytical science within the gene therapy sector. His responsibilities include designing and conducting cell-based, DNA, and protein assays specifically for novel gene therapy products. His work contributes to the quality control processes essential for the development and validation of therapeutic products.
Education and Expertise
Harry Walmsley studied at Victoria University of Wellington, where he earned a Bachelor of Biomedical Science with a focus on Molecular Pathology from 2011 to 2016. His academic background provides a strong foundation for his current role in gene therapy, particularly in the development of assays tailored for therapeutic applications. His expertise lies in analytical techniques critical for assessing gene therapy products.
Background
Before joining MeiraGTx, Harry Walmsley worked as a Scientific Officer at Patheon from 2018 to 2019. During his nine-month tenure in Swindon, England, he gained valuable experience in the pharmaceutical industry, which enhanced his skills in analytical science. This background has equipped him with the knowledge necessary to excel in his current position in gene therapy.
Achievements in Gene Therapy
Harry Walmsley has made significant contributions to the field of gene therapy through his role as a QC Analytical Scientist. He is responsible for developing assays that are critical for the evaluation of novel gene therapy products. His work in designing and performing various assays plays a vital role in ensuring the efficacy and safety of these therapeutic innovations.